OUR NEWS & EVENTS

EpiEndo Pharmaceuticals Secures €20M Series A Funding to Advance Clinical Development of its Lead Compound EP395 for the Treatment of COPD

EpiEndo is announced as the winner of the Biotech & Pharmaceuticals category, at the European Innovation Council Investor Day on Health 2021

EpiEndo Pharma is the recipient of a €2.7 million convertible loan from the European Innovation Council (EIC) Fund.

First-in-Human Clinical Trial of EpiEndo’s Lead Compound, EP395, for Chronic Inflammatory Airway Diseases Commences at the Medicines...

EpiEndo Pharmaceuticals is pleased to announce the appointment of Dr. Sigríður Valgeirsdóttir and Robert Helgason to the Company’s Board

EpiEndo Pharmaceuticals is pleased to announce that their consortium project EPIcoliX has been officially recognized as a Eurostar...

EpiEndo Pharma Builds Science and Medical Leadership with Appointment of New CSO & CMO

REYKJAVIK, ICELAND – 24 February 2021 – EpiEndo Pharmaceuticals (www.epiendo.com) The Board of EpiEndo Pharmaceuticals is pleased to...

REYKJAVIK, ICELAND - 5 January 2021 - EpiEndo Pharmaceuticals (www.epiendo.com) announced today that the Company has received approval...

REYKJAVIK, ICELAND – 21 September 2020 – EpiEndo Pharmaceuticals (www.epiendo.com) is pleased to share important findings in a poster at...

For 6 years, the LSX World Congress has been bringing together the executives that matter to the future of healthcare and life sciences.

EpiEndo is very proud to be among 75 promising start-ups and SMEs to be selected by the European Innovation Council (EIC) to receive a grant

EpiEndo’s Founder, Fridrik Runar Gardarsson and Finnur Fridrik Einarsson (COO) will represent EpiEndo at the RESI conference in Boston on...

EpiEndo successfully closed our 4th seed round of 2 million Euros.

EpiEndo’s CEO, Fredrik Lehmann will represent EpiEndo at Nordic Life Science Days in Malmö on the 10th to 12th of September. He will also...

EpiEndo welcomes Jennifer Kricker, PhD to the team. Jennifer will take the role of Project Director. Jennifer has been involved with...

EpiEndo has been nominated for the Nordic Life Science Business Class and Deligates choice Awards EpiEndo is among 9 BioTechs that are...

EpiEndo is proud to introduce new external advisers to our Scientific Advisory Board (SAB) and welcome Professors Peter Barnes, Dave...

EpiEndo is pleased to announce that we have successfully closed a financing round of ISK 110 million (800.000 EUR). The financing was led...

EpiEndo is pleased to welcome Fredrik Lehmann to our team as the new CEO of EpiEndo. Fredrik has a PhD in Medicinal Chemistry from the...